Vertex researcher, paul negulescu ph.d., receives the 2025 canada gairdner international award for pioneering research and discovery of medicines for cystic fibrosis

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that paul negulescu, ph.d. senior vice president, vertex has been awarded the 2025 canada gairdner international award “for pioneering research into the cellular and molecular mechanisms underlying the genetic disease cystic fibrosis, leading to the development of transformative drug therapies based on these mechanisms, thereby improving and saving countless lives.” negulescu shares the award with michae.
VRTX Ratings Summary
VRTX Quant Ranking